# Concurrent Neoadjuvant Chemo/Endocrine Therapy in HER2+ Breast Cancer

> **NCT07506876** · PHASE2 · RECRUITING · sponsor: **Legacy Health System** · enrollment: 30 (estimated)

## Conditions studied

- Breast Cancer - Infiltrating Ductal Carcinoma
- HER-2 Positive Breast Cancer

## Interventions

- **DRUG:** Concurrent endocrine therapy with the chemotherapy and HER2 directed therapy

## Key facts

- **NCT ID:** NCT07506876
- **Lead sponsor:** Legacy Health System
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-27
- **Primary completion:** 2027-12
- **Final completion:** 2027-12
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07506876

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07506876, "Concurrent Neoadjuvant Chemo/Endocrine Therapy in HER2+ Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07506876. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*